Pfizer Wins Bid To Invalidate GSK’s Patents Relating To RSV Vaccine

Reuters (10/7, Tobin, Fick) reports, “Pfizer on Monday won a bid in a London court to invalidate two of GSK’s patents relating to a respiratory syncytial virus (RSV) vaccine.” A spokesperson for GSK said the ruling “has no impact on our ability to launch and market Arexvy anywhere in the world, including in the UK.” The spokesperson added, “We continue to believe our patents are valid and infringed by Pfizer and will seek to appeal this decision.”